Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I
Executive Summary
Only 8% of original ANDAs submitted in the user fee program’s third year were approved on the first cycle, compared with 72% that received a complete response letter.
You may also be interested in...
Complex ANDAs: Early Meetings With FDA Can Generate Bonus Communication
By conducting a product development or pre-submission meeting, sponsors can receive a mid-review cycle meeting for a complex product ANDA.
Complex ANDAs: Early Meetings With FDA Can Generate Bonus Communication
By conducting a product development or pre-submission meeting, sponsors can receive a mid-review cycle meeting for a complex product ANDA.
FDA's Generic Approvals Catch A Bit Of Breath In July But Continue At Fast Pace
US Generic drug approvals drop in July, but still are above the monthly average for the year, potentially signaling a new expected output.